ArticleBritish journal of cancer2025
Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.
Article in British journal of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Cabozantinib for advanced grade 3 neuroendocrine tumors: subgroup analysis of the phase 3 CABINET trial (Alliance A021602).Endocrine-related cancer · 2026Trial
- Neuroendocrine Carcinoma of the Gallbladder: Clinicopathologic and Immunohistochemical Analysis of 31 Cases.The American journal of surgical pathology · 2026Article
- Genetic intratumour heterogeneity in digestive high-grade neuroendocrine neoplasms.Journal of neuroendocrinology · 2026Article
- What are the Unmet Needs in Managing Digestive Neuroendocrine Carcinomas?Current oncology reports · 2026Review
- Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): An Aggressive Disease Course and Limitations for Personalized Oncology.Oncology and therapy · 2026Article
- Article
- Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.International journal of cancer · 2026Article
- Efficacy and safety of surufatinib and sintilimab with or without chemotherapy for advanced high-grade neuroendocrine neoplasms and pancreatic cancer.NPJ precision oncology · 2026Article
- Morphology first: preserving diagnostic hierarchies in high-grade neuroendocrine neoplasms across organ sites.Endocrine · 2026Article
- Role of tumor markers before or during chemotherapy for digestive neuroendocrine carcinomas as an exploratory analysis of JCOG1213.Scientific reports · 2026Article
- Real World Outcomes With Chemotherapy and Immunotherapy in Metastatic Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas.Cancer medicine · 2026Article
- Proliferative escalation and possible neuroendocrine carcinoma transformation in pulmonary metastases of a cervical neuroendocrine tumor: A case report.Oncology letters · 2026Article
- Efficacy of surufatinib in advanced Grade 3 neuroendocrine tumors: a real-world, national, multicenter study.Therapeutic advances in medical oncology · 2026Article
- Association of primary-site surgery with survival in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma: a population-based SEER study (2004-2023).Frontiers in oncology · 2026Article
- Integrated local and global Ki67 profiling for prognostic stratification and therapeutic guidance in high-grade neuroendocrine neoplasms: a multicenter validation study.International journal of surgery (London, England) · 2025Article
- Nab-paclitaxel plus bevacizumab for patients with metastatic extrapulmonary neuroendocrine carcinoma: a phase 2 single-arm study.EClinicalMedicine · 2025Article
- Controversies in NEN: An ENETS position statement on the treatment of patients with Grade 3 well-differentiated neuroendocrine tumours of the gastro-enteropancreatic tract.Journal of neuroendocrinology · 2025Review
- Prognostic impact of primary tumor resection and nomogram development for survival prediction in colonic neuroendocrine carcinoma patients with liver metastasis: a SEER database-based study.Discover oncology · 2025Article
- Review
- DNA methylation patterns facilitate tracing the origin of neuroendocrine neoplasms.Nature communications · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDigestive high-grade neuroendocrine neoplasms (HG-NEN) are rare and classified as neuroendocrine carcinomas (NEC) or neuroendocrine tumours G3 (NET G3), and differ in clinical and molecular characteristics, response to treatment and prognosis.
methodsProspective multicenter study registering clinical data on patients with digestive HG-NEN. Treatment outcome in patients with advanced disease was compared after centralized pathological re-evaluation.
results427 NEC and 117 NET G3 received palliative chemotherapy. Immediate progression rate was 41% and 24%, progression-free survival (PFS) 3.4 m and 7.4 m, overall survival (OS) 7.4 m and 21.8 m for NEC and NET G3, respectively. Significant factors for OS in NEC were performance status (PS), Ki-67 > 55%, alkaline phosphatase (ALP), age, sex and for PFS colorectal primary and PS. NEC Ki-67 < 55% had similar OS comparing treatment. Significant factors for OS in NET G3 were platinum-based treatment, PS, age and ALP, and for PFS platinum-based treatment.
conclusionsSurvival was shorter than expected in this unique population-based cohort of advanced digestive HG-NEN, likely due to inclusion of elderly and patients with poor PS. Several novel prognostic factors were identified for NEC and NET G3. An initial sub-effective platinum-based treatment for NET G3 could not be compensated by later-line treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.